GASC1 Inhibitor Caffeic Acid for Squamous Esophageal Cell Cancer (ESCC)
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
Caffeic acid can target inhibit GASC1 (gene amplified in squamous cell carcinoma 1, also
known as KDM4C and JMJD2C) expression and GASC1 is confirmed to be a new oncogene in several
cancers including esophageal cancer. This study aims to investigate the efficiency and safety
of coffeic acid in chinese advanced esophageal squamous cell cancer (ESCC).
Phase:
Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital of Henan University of Science and Technology